Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

Journal Articles

CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation

Trang Vu, Ruchi P. Patel, Steven Yang, Dean Qian, Stefan K. Barta, Nicholas A. Siciliano, Marco Ruella, Adam E. Snook

Blood (2024) 144 (Supplement 1): 500.

https://doi.org/10.1182/blood-2024-203590

Published: 2024

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

Guido Ghilardi, Emeline R. Chong, Luca Paruzzo, Giulia Gabrielli, Sunita D. Nasta, Vrutti Patel, Eugenio Fardella, Daniel J. Landsburg, Jordan Carter, Colin Thomas, Stefan K. Barta, Elise A. Chong, Jakub Svoboda, Marco Ruella, Stephen J. Schuster

Blood (2024) 144 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2024-206027

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

Michael Schneider, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael Roderick Cook, Nasheed Hossain, Stephen J. Schuster, Heather Difilippo, John P Plastaras, Michael Lariviere, Marco Ruella, David L. Porter, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 5123.

https://doi.org/10.1182/blood-2024-202736

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

Ruchi P. Patel, Trang Vu, Dean Qian, Yunlin Zhang, Guido Ghilardi, Steven Yang, Stefan K. Barta, Nicholas A. Siciliano, Adam E. Snook, Marco Ruella

Blood (2024) 144 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2024-210255

Published: 2024

Journal Articles

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Siena Nason, Ziqi Yang, Guido Ghilardi, Luca Paruzzo, Alberto Carturan, Eugenio Fardella, Puneeth Guruprasad, Anushka Anant Padmanabhan, Tatiana Blanchard, Gerald Linette, Beatriz M. Carreno, Sandra Susanibar-Adaniya, Alfred L. Garfall, Marco Ruella, Patrizia Porazzi

Blood (2024) 144 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2024-206011

Published: 2024

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Blood (2023) 142 (20): 1724–1739.

https://doi.org/10.1182/blood.2023020400

Published: 2023

Includes: Supplemental data

Journal Articles

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Puneeth Guruprasad, Mathew G. Angelos, Raymone Pajarillo, Khatuna Gabunia, Chong Xu, Tatiana Blanchard, John Scholler, Patrizia Porazzi, Gerald Linette, Beatriz M. Carreno, Marco Ruella

Blood (2023) 142 (Supplement 1): 102.

https://doi.org/10.1182/blood-2023-186611

Published: 2023

Journal Articles

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, Yusuke Isshiki, Guido Ghilardi, Siena Nason, Ziqi Yang, Alberto Carturan, Linhui Chen, Yunlin Zhang, Ruchi P. Patel, Puneeth Guruprasad, Ositadimma Ugwuanyi, Ivan J Cohen, Stephen J Schuster, Ari M Melnick, Wendy BÃ©guelin, Marco Ruella

Blood (2023) 142 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2023-182440

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Mathew G. Angelos, Ruchi P. Patel, Yi-Hao Chiang, Wei Xie, Raymone Pajarillo, Carolyn E. Shaw, Ekta Singh, Jason Xu, Avery D. Posey, Alain Rook, Antonia Rotolo, Vinodh Pillai, Stefano A. Pileri, David T. Teachey, Marco Ruella

Blood (2023) 142 (Supplement 1): 885.

https://doi.org/10.1182/blood-2023-181282

Published: 2023

Journal Articles

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Yusuke Isshiki, Patrizia Porazzi, Xi Chen, Matthew Teater, Ioannis Karagiannidis, Henna S. Nam, Ari M Melnick, Marco Ruella, Wendy BÃ©guelin

Blood (2023) 142 (Supplement 1): 432.

https://doi.org/10.1182/blood-2023-190610

Published: 2023

Journal Articles

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Benjamin Frost, Jennifer JD Morrissette, Stephen J Schuster, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Elise A. Chong, Marco Ruella, Adam Bagg, Daniel J. Landsburg

Blood (2023) 142 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2023-186553

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only